Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine

JS Heyman, CL Williams, TF Burks, HI Mosberg and F Porreca

Department of Pharmacology, University of Arizona Health Sciences Center, Tucson.

The effect of pretreatment with naloxonazine on opioid-mediated antinociception against a thermal stimulus (55 degrees C warm-water tail-flick test) and inhibition of gastrointestinal transit at supraspinal and spinal levels was studied in unanesthetized mice. The mu-selective agonist [D-Ala2, N-methyl-Phe4, Gly5-ol]enkephalin (DAGO), the delta-selective agonist [D-Pen2, D-Pen5]enkephalin (DPDPE) and the reference mu-acting agonist morphine, all produced antinociception after either i.c.v. or intrathecal(ly) (i.t.) administration. Morphine and DAGO, but not DPDPE, inhibited gastrointestinal transit after i.c.v. administration, whereas all three agonists slowed gut propulsion when given i.t. A single s.c. naloxonazine pretreatment, 35 mg/kg given 24 hr earlier, failed to displace the dose-response line for i.c.v. DPDPE antinociception but produced a marked rightward displacement of the i.c.v. morphine and DAGO dose-response lines for antinociception. In contrast, naloxonazine (35 mg/kg) pretreatment did not alter the antinociceptive effects of i.t. morphine, DAGO or DPDPE. The effects of naloxonazine pretreatment on inhibition of gut propulsion were the converse of those observed for antinociception at supraspinal and spinal sites; naloxonazine had no effect on the antitransit properties of i.c.v. morphine and DAGO but inhibited the antitransit properties of all three agonists when they were given i.t. These results support the view that opioids may produce their supraspinal antitransit effects at a receptor different from that mediating antinociception; morphine and DAGO mediate their antitransit effects at a naloxonazine-insensitive site, whereas their antinociceptive effects are produced at the naloxonazine-sensitive receptor.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 245, Issue 1, pp. 238-243, 04/01/1988
Copyright © 1988 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				L. Mahurter, C. Garceau, J. Marino, H. Schmidhammer, G. Toth, and G. W. Pasternak Separation of Binding Affinity and Intrinsic Activity of the Potent {micro}-Opioid 14-Methoxymetopon J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 247 - 253. [Abstract] [Full Text] [PDF]

				Y.-X. Pan, J. Xu, E. Bolan, H. S. Moskowitz, M. Xu, and G. W. Pasternak Identification of Four Novel Exon 5 Splice Variants of the Mouse {micro}-Opioid Receptor Gene: Functional Consequences of C-Terminal Splicing Mol. Pharmacol., September 1, 2005; 68(3): 866 - 875. [Abstract] [Full Text] [PDF]

				Y. Jinsmaa, Y. Okada, Y. Tsuda, K. Shiotani, Y. Sasaki, A. Ambo, S. D. Bryant, and L. H. Lazarus Novel 2',6'-Dimethyl-L-Tyrosine-Containing Pyrazinone Opioid Mimetic {micro}-Agonists with Potent Antinociceptive Activity in Mice J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 432 - 438. [Abstract] [Full Text]

				E. A. Bolan, R. J. Tallarida, and G. W. Pasternak Synergy between {micro} Opioid Ligands: Evidence for Functional Interactions among {micro} Opioid Receptor Subtypes J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 557 - 562. [Abstract] [Full Text] [PDF]

				S. M. South and M. T. Smith Apparent Insensitivity of the Hotplate Latency Test for Detection of Antinociception Following Intraperitoneal, Intravenous or Intracerebroventricular M6G Administration to Rats J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1326 - 1332. [Abstract] [Full Text]